Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) reached a new 52-week low on Thursday. The stock traded as low as $2.61 and last traded at $2.62, with a volume of 7,081 shares trading hands. The stock had previously closed at $2.68.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group raised Raia Drogasil to a “buy” rating and set a $5.20 price objective on the stock in a report on Sunday, October 18th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Raia Drogasil has a consensus rating of “Moderate Buy” and an average price target of $5.20.
Check Out Our Latest Stock Report on Raia Drogasil
Raia Drogasil Stock Down 2.1%
The company has a debt-to-equity ratio of 0.99, a current ratio of 1.41 and a quick ratio of 0.58. The company’s 50-day simple moving average is $3.60 and its 200 day simple moving average is $4.01. The firm has a market cap of $3.45 billion and a P/E ratio of 17.47.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. Raia Drogasil had a net margin of 2.89% and a return on equity of 20.61%. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.43 billion. Research analysts anticipate that Raia Drogasil S.A. will post 0.17 EPS for the current fiscal year.
About Raia Drogasil
Raia Drogasil, now known as RD Saúde, is a Brazilian health and pharmacy retail company formed in 2011 through the merger of Droga Raia and Drogasil. It operates pharmacy stores under the Raia and Drogasil brands. The company sells prescription and over-the-counter medicines, personal care and beauty products, and other health and wellness goods. It serves customers across Brazil through its retail locations and digital channels, including online ordering and delivery. In addition to pharmacy retail, RD Saúde provides health-related services through its stores and digital platforms.
Further Reading
- Five stocks we like better than Raia Drogasil
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
- 3 Pharmaceutical Stocks That Offer Safety and Growth
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
- CoreWeave’s Backlog Is Surging—Can the Stock Follow?
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
